Mostrar registro simples

dc.contributor.authorAlbillos García, Silvia María 
dc.contributor.authorMontero, Olimpio
dc.contributor.authorCalvo Meruelo, Sara
dc.contributor.authorSolano, Berta
dc.contributor.authorTrejo Gabriel y Galán, José Mª
dc.contributor.authorCubo Delgado, Esther 
dc.date.accessioned2021-06-28T09:38:03Z
dc.date.available2021-06-28T09:38:03Z
dc.date.issued2021-05
dc.identifier.urihttp://hdl.handle.net/10259/5817
dc.description.abstractBackground: Studies have revealed controversial results regarding the diagnostic accuracy of plasma α-synuclein levels in patients with Parkinson’s disease (PD). This study was aimed to analyze the diagnostic accuracy of plasma α-synuclein in PD versus healthy controls and patients with essential tremor (ET). Methods: In this cross-sectional study, we included de novo (n = 19) and advanced PD patients [OFF (n = 33), and On (n = 35) states], patients with ET (n = 19), and controls (n = 35). The total plasma α-synuclein levels were determined using an ELISA sandwich method. We performed adjusted multivariate regression analysis to estimate the association of α-synuclein levels with group conditions [controls, ET, and de novo, OFF and ON-PD]. We studied the diagnostic accuracy of plasma α-synuclein using the area under the curve (AUC). Results: The plasma α-synuclein levels were higher in controls compared to PD and ET (p < 0.0001), discriminating de novo PD from controls (AUC = 0.74, 95% CI 0.60–0.89), with a trend towards in advanced PD (OFF state) from ET (AUC = 0.69, 95% CI 0.53–0.84). Conclusions: This is the first study examining and comparing plasma α-synuclein levels in ET vs. PD and controls. Preliminary findings suggest that plasma α-synuclein levels might help to discriminate de novo and advanced PD from controls and ET.en
dc.description.sponsorshipJunta de Castilla y León is acknowledged for funding through the Biomedicine open project call (Ref. BIO/BU06/14)es
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherUbiquity Presses
dc.relation.ispartofTremor and Other Hyperkinetic Movements. 2021, V. 11, n. 1: 20, pp. 1–8.es
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectParkinson’s diseaseen
dc.subjectEssential tremoren
dc.subjectalpha-synucleinen
dc.subjectplasma biomarkeren
dc.subjectdiagnosisen
dc.subject.otherBioquímicaes
dc.subject.otherBiochemistryen
dc.subject.otherBiología moleculares
dc.subject.otherMolecular biologyen
dc.titleCan plasma α-Synuclein help us to differentiate parkinson’s disease from essential tremor?en
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.publisherversionhttps://doi.org/10.5334/tohm.600es
dc.identifier.doi10.5334/tohm.600
dc.relation.projectIDinfo:eu-repo/grantAgreement/JCyL/BIO/BU06/14
dc.identifier.essn2160-8288
dc.journal.titleTremor and Other Hyperkinetic Movementses
dc.volume.number11es
dc.issue.number1es
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Arquivos deste item

Thumbnail

Este item aparece na(s) seguinte(s) coleção(s)

Mostrar registro simples